This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



lidocaine/prilocaine (Senstend®)


Reference No. 4384

Publication date:
16/06/2020


Appraisal information

lidocaine/prilocaine (Senstend®) 150/ 50 mg/ml cutaneous solution


Company: Plethora Solutions Holdings PLC
BNF category: Unspecified
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 15/06/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, lidocaine/prilocaine (Senstend®) cannot be endorsed for use within NHS Wales for the treatment of primary premature ejaculation in adult men
Statement of Advice (SOA)
Download